NK-One Therapeutics is a Wayne, Pennsylvania biotechnology company developing a precision therapy for refractory cancer pain. Its lead program, Substance P-Saporin (SP-SAP), licensed from Advanced Targeting Systems, is given as a single intrathecal administration to selectively disable NK-1 receptor-expressing pain neurons in the spinal dorsal horn while preserving protective acute pain signaling. The company holds worldwide development rights to SP-SAP for human and veterinary use; a Phase 1 human trial is underway and a large canine clinical trial has been completed.